Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new medication to see if it can help prevent migraines in adults with MOH.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 485 Patients • NCT04152083Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was diagnosed with migraines before or at the age of 50.I've had 15 or more headache days each month for the last 3 months.I have been diagnosed with a jaw joint disorder.I have had 8 or more migraine days each month for the last 3 months.I've had 15 or more headache days each month for the last 3 months.I was diagnosed with migraines before or at the age of 50.I have been diagnosed with migraine or medication overuse headache.I have been diagnosed with a specific type of severe or unusual headache.I've had 15 or more headache days each month for the last 3 months.I've had 15 or more headache days each month for the last 3 months.I was diagnosed with migraines before or at the age of 50.My psychiatric condition has been stable and treated for at least 6 months.I have a significant pain condition like fibromyalgia or chronic back pain.I have a history of serious heart or blood vessel problems.I have been diagnosed with migraine or medication overuse headache.I was diagnosed with migraines before or at the age of 50.I have had 8 or more migraine days each month for the last 3 months.
- Group 1: Eptinezumab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this trial accept participants who are of age twenty and above?
"This research is inviting individuals aged between 18 and 75 years old to take part in the study."
Are there still opportunities to join this clinical experiment?
"The clinical trial is actively searching for participants, as evidenced on ClinicalTrials.gov which lists the trial's initial posting date of July 1st 2022 and most recent edit made on November 11th 2022."
Who is eligible to join this research endeavor?
"To be eligible for this research, potential participants must have been diagnosed with migraine and fall into the age range between 18 to 75 years. Altogether, 570 individuals will be recruited."
In what geographic areas is this investigation accessible?
"Clinvest Research LLC in Springfield, Missouri, Clinical Research of Central Florida - ClinEdge - PPDS in Winter Haven, Florida and Legacy Clinical Solutions: Tandem Clinical Research, LLC- Clinedge - Louisiana - PPDS in Marrero are the primary locations for this study. There are also 6 other sites where patients can participate."
What potential adverse reactions should patients be aware of when using Eptinezumab?
"Our team at Power has rated the safety of Eptinezumab as a 3, due to it being approved for use and having gone through numerous phases of clinical trials."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger